Evidence map›Paper›PMID 40696274›Full record

Trial reportBMC anesthesiology2025

Combining ropivacaine transversus abdominis plane block with intravenous lidocaine infusion in adults undergoing colorectal cancer surgery: an open-label, dose-escalation exploratory trial.

Mengmeng Zhou, Feng Yu, Yan Xu, Jingwen Wu, Lajing Luowu, Qianqian Tang, Xiaoting Hao, Kun Shao, Mao Ye, Lulong Bo and 2 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06006026 (The Safety of Ropivacaine Transversus Abdominis Plane Block Combined With Intravenous Lidocaine in Patients Undergoing Colorectal Cancer Surgery), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06006026 naunknown statusnot on this map

The Safety of Ropivacaine Transversus Abdominis Plane Block Combined With Intravenous Lidocaine in Patients Undergoing Colorectal Cancer Surgery: a Single Center, Open Label Dose Escalation Study

TypeinterventionalSponsorWest China HospitalRan2023 to 2024Enrolled9ConditionsColorectal CancerArmsRopivacaine Hydrochloride 10 MG/ML [Naropin]
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mengmeng Zhou *Department of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China.
Feng Yu *Department of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China.
Yan XuDepartment of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China.
Jingwen WuDepartment of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China.
Lajing LuowuDepartment of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China.
Qianqian TangDepartment of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China.
Xiaoting HaoDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Kun ShaoDepartment of Anaesthesiology, Xinxiang Central Hospital, Xinxiang, China.
Mao YeDepartment of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China.
Lulong BoFaculty of Anaesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China.
Li ZhouDepartment of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China. zlmz@wchscu.cn.
Chunling JiangDepartment of Anaesthesiology, West China Hospital, The Research Units of West China (2018RU012), Sichuan University, Chinese Academy of Medical Sciences, Chengdu, China. jiangchunling@scu.edu.cn.

Funding

Sichuan Science and Technology Program 2023ZYD0168Wu JiePing Medical Foundation 320.6750.2022-05-3
6 · The paper itself

Abstract

backgroundThe concurrent use of a ropivacaine transversus abdominis plane (TAP) block with intravenous lidocaine infusion, though effective for pain relief, raises safety concerns regarding local anesthetic systemic toxicity (LAST). This study aimed to assess the dose-risk relationship of LAST in this combination by escalating the ropivacaine dose while fixing the lidocaine dose.

methodsIn this dose-escalation study, adult patients undergoing colorectal cancer surgery received a 0.2% ropivacaine TAP block (1.5, 2.0 or 2.5 mg kg

resultsNine patients were included in the per-protocol analysis, and 26 were included in the intention-to-treat analysis. No signs of LAST were observed. Plasma ropivacaine concentrations remained consistently below 2.2 µg mL

conclusionAlthough no signs of LAST were observed with the combination of a 1.5 to 2.5 mg kg

trial registrationThis trial was registered at ClinicalTrials.gov (NCT06006026) on 23 August 2023.

Indexed as

Anesthetics, LocalColorectal NeoplasmsLidocaineNerve BlockRopivacaineAbdominal MusclesAdultAgedDose-Response Relationship, DrugFemaleHumansInfusions, IntravenousMaleMiddle AgedPostoperative PainAnesthetics, LocalLidocaineRopivacaineTransversus abdominis plane, Ropivacaine, Intravenous lidocaine, Local anesthetic systemic toxicity, Dose-escalation

Identifiers

PMID40696274
PMCPMC12281678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.